31 – 40 of 383
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
(
- Contribution to journal › Article
-
Mark
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
(
- Contribution to journal › Article
- 2017
-
Mark
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus : Results over 52 weeks
(
- Contribution to journal › Article
-
Mark
Influences of breakfast on clock gene expression and postprandial glycemia in healthy individuals and individuals with diabetes : A randomized clinical trial
(
- Contribution to journal › Article
-
Mark
High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA1C in Type 2 diabetes
(
- Contribution to journal › Article
-
Mark
The vildagliptin experience - 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration
(
- Contribution to journal › Article
-
Mark
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus : Long-term efficacy with or without rescue therapy
(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide : effects alone and in combination on insulin secretion and glucose disappearance in mice
(
- Contribution to journal › Article
-
Mark
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day : An analysis using continuous glucose monitoring
(
- Contribution to journal › Article
-
Mark
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes : A randomized, open-label, 2-arm parallel comparative, exploratory trial
(
- Contribution to journal › Article